VEO Ophthalmics, LLC articles

Aramis Biosciences announced that the first patient has been dosed in its phase 2 proof of concept clinical trial evaluating A197, a novel, first-in-class, topical immunomodulatory agent for the treatment of dry eye disease.

“This is an important milestone for Aramis Biosciences and a hopeful moment for dry eye patients given the suboptimal efficacy and tolerability limitations commonly associated with available treatments," David S. Tierney, MD, Aramis Biosciences’ P

The first stand-alone prosthetic iris has received regulatory approval in the United States. CustomFlex Artificial Iris (HumanOptics) is a flexible silicone device indicated for adults and children with congenital aniridia or iris defects due to albinism, traumatic injury or surgical removal. 

“Today’s approval of the first artificial iris provides a novel method to treat iris defects that reduces sensitivity to bright light and glare,” said Malvina Eydelman, MD